Published in J Natl Cancer Inst on June 01, 1969
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 7.86
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 7.17
Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med (1988) 7.12
Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A (1987) 6.90
The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science (1989) 6.89
Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J Immunol (1987) 5.64
The functional relationship of the interleukins. J Exp Med (1980) 5.62
Characterization of lymphocyte-activating factor (LAF) produced by the macrophage cell line, P388D1. I. Enhancement of LAF production by activated T lymphocytes. J Immunol (1978) 5.36
Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med (1982) 5.33
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med (1993) 4.94
Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science (1993) 4.75
Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med (1989) 4.64
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood (2000) 4.34
Relationship of in vitro lymphocyte transformation to delayed hypersensitivity in guinea pigs and man. Fed Proc (1990) 4.31
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol (1983) 4.25
The transformation of column-purified lymphocytes with nonspecific and specific antigenic stimuli. J Immunol (1968) 4.24
Interleukin 1: an immunological perspective. Annu Rev Immunol (1985) 4.09
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
Transformation and chromosome changes induced by Epstein-Barr virus in normal human leukocyte cultures. Proc Natl Acad Sci U S A (1969) 3.72
Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med (1965) 3.54
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine (1989) 3.39
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Delayed hypersensitivity in the guinea-pig to a protein-hapten conjugate and its relationship to in vitro transformation of lymph node, spleen, thymus and peripheral blood lymphocytes. Immunology (1967) 3.33
Efficient transfer of highly resolved small DNA fragments from polyacrylamide gels to DBM paper. Gene (1980) 3.30
Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem Biophys Res Commun (1989) 3.09
Synergistic interaction of macrophages and lymphocytes in antigen-induced transformation of lymphocytes. J Exp Med (1970) 3.08
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol (2001) 3.02
Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science (1972) 2.91
Murine epidermal cell-derived thymocyte-activating factor resembles murine interleukin 1. J Immunol (1982) 2.90
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem (1996) 2.78
PIK3CA as an oncogene in cervical cancer. Oncogene (2000) 2.75
Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). J Immunol (1981) 2.74
Bidirectional amplification of macrophage-lymphocyte interactions: enhanced lymphocyte activation factor production by activated adherent mouse peritoneal cells. J Immunol (1977) 2.73
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med (1975) 2.71
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen. Cell Immunol (1981) 2.60
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today (1992) 2.56
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Properties of a specific interleukin 1 (IL 1) receptor on human Epstein Barr virus-transformed B lymphocytes: identity of the receptor for IL 1-alpha and IL 1-beta. J Immunol (1986) 2.49
Macrophage-mediated suppression. I. Evidence for participation of both hdyrogen peroxide and prostaglandins in suppression of murine lymphocyte proliferation. J Immunol (1980) 2.47
Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol (1986) 2.40
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med (1990) 2.40
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol (1999) 2.38
A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med (1999) 2.32
Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol (2000) 2.32
Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor. Immunology (1989) 2.31
Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol (1985) 2.31
Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest (1995) 2.29
Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A (1988) 2.26
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Chromosome translocation in peripheral neuroepithelioma. N Engl J Med (1984) 2.22
Regulation of murine macrophage Ia-antigen expression by products of activated spleen cells. J Exp Med (1980) 2.19
A human mononuclear leukocyte chemotactic factor: characterization, specificity and kinetics of production by homologous leukocytes. J Immunol (1973) 2.18
Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med (1994) 2.18
Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol (1990) 2.10
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med (1974) 2.08
New insights into the biology of the acute phase response. J Clin Immunol (1999) 2.05
Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet (1986) 2.04
Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors. J Immunol (1980) 2.04
Chemotactic properties of partially purified human epidermal cell-derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells. J Immunol (1983) 2.03
Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol (1985) 2.02
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med (1974) 2.02
Accessory cell function of human B cells. I. Production of both interleukin 1-like activity and an interleukin 1 inhibitory factor by an EBV-transformed human B cell line. J Exp Med (1984) 2.02
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science (1982) 2.02
Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons. J Clin Invest (1984) 2.00
Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci U S A (1990) 1.94
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (1990) 1.93
Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J (2000) 1.93
Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem (1995) 1.92
Characterization of lymphocyte-activating factor (LAF) produced by a macrophage cell line, P388D1. II. Biochemical characterization of LAF induced by activated T cells and LPS. J Immunol (1978) 1.92
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Lymphocyte transformation in human Plasmodium falciparum malaria. J Immunol (1974) 1.91
Lymphokines: their role in lymphocyte responses. Properties of interleukin 1. Fed Proc (1982) 1.90
Second malignancies complicating Hodgkin's disease in remission. Lancet (1975) 1.90
Relationship of cell cycle to recovery of IL 2 activity from human mononuclear cells, human and mouse T cell lines. J Immunol (1981) 1.88
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res (1978) 1.88
Interleukin 8 (monocyte-derived neutrophil chemotactic factor) dynamically regulates its own receptor expression on human neutrophils. J Biol Chem (1990) 1.87
Clinical trials with adriamycin. Cancer (1971) 1.86
Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci U S A (1988) 1.86
Chemokines, inflammation and the immune system. Ther Immunol (1994) 1.86
Phorbol myristic acetate stimulates LAF production by the macrophage cell line, P388D. Cell Immunol (1978) 1.86
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Defective lymphocyte transformation and delayed hypersensitivity in Wiskott-Aldrich syndrome. J Immunol (1970) 1.85
Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor. J Immunol (1983) 1.84